Summit Tx Capital, L.P. Viridian Therapeutics, Inc.\De Put Options Transaction History
Summit Tx Capital, L.P.
- $2.32 Trillion
- Q1 2025
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding VRDN
# of Institutions
189Shares Held
79.5MCall Options Held
92.2KPut Options Held
55.2K-
Deep Track Capital, LP Greenwich, CT5.38MShares$68.4 Million2.54% of portfolio
-
Black Rock Inc. New York, NY4.77MShares$60.7 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ4.7MShares$59.8 Million5.34% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.56MShares$58 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$49.4 Million12.64% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $507M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...